…
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform offers the Allurion Program, a swallowable and procedure-less intragastric balloon for weight loss, as well as provides access to artificial intelligence-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company operates in Spain, France, Turkey, and internationally. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Allurion Technologies develops a non-surgical, single-use gastric balloon and an associated digital weight-management program for treating obesity without endoscopy or anesthesia. It may benefit from rising obesity prevalence, demand for less invasive therapies, international expansion and interest in integrated device-plus-telehealth offerings that could support recurring service revenue and broader adoption.
Key risks include regulatory and safety reviews, significant competition from GLP-1 obesity drugs and surgical or endoscopic alternatives, uncertain reimbursement and commercialization execution, and concentration risk from reliance on a limited product portfolio.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -28.68M | -25.43M | -80.34M | -37.60M | -12.39M |
| Net income | -28.75M | -26.15M | -82.30M | -37.74M | -12.39M |
| Selling general administrative | 21.35M | 28.40M | 46.02M | 15.37M | 8.82M |
| Selling and marketing expenses | 10.80M | 25.93M | 46.86M | 50.41M | 27.14M |
| Gross profit | 9.57M | 21.50M | 41.50M | 50.73M | 29.19M |
| Reconciled depreciation | 0.98M | 1.00M | 1.91M | 2.00M | 0.71M |
| Ebit | -28.68M | -23.17M | -69.78M | -33.17M | -13.06M |
| Ebitda | -27.70M | -22.17M | -69.03M | -32.28M | -12.35M |
| Depreciation and amortization | 0.98M | 1.00M | 0.75M | 0.90M | 0.71M |
| Operating income | -30.16M | -50.20M | -79.08M | -32.01M | -12.50M |
| Other operating expenses | 45.39M | 82.31M | 132.54M | 96.22M | 50.74M |
| Interest expense | 0.00M | 2.26M | 10.57M | 4.43M | 3.67M |
| Tax provision | 0.07M | 0.72M | 0.14M | 0.14M | 0.00M |
| Net interest income | 0.00M | -2.26M | -9.09M | -4.43M | -3.67M |
| Income tax expense | 0.07M | 0.72M | 0.26M | 0.14M | 3.11M |
| Total revenue | 15.23M | 32.11M | 53.47M | 64.21M | 38.24M |
| Total operating expenses | 39.73M | 71.70M | 120.58M | 82.74M | 41.69M |
| Cost of revenue | 5.66M | 10.61M | 11.97M | 13.48M | 9.05M |
| Total other income expense net | 1.48M | 24.77M | -1.26M | -5.59M | 0.12M |
| Net income from continuing ops | -28.75M | -26.15M | -73.78M | -37.74M | -12.39M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 15.77M | 32.81M | 71.71M | 51.37M | 39.35M |
| Other current assets | 0.76M | 1.24M | 2.41M | 2.49M | 1.94M |
| Total liab | 92.96M | 110.79M | 142.20M | 122.81M | 73.64M |
| Total stockholder equity | -77.19M | -77.98M | -70.49M | -71.44M | -34.28M |
| Other current liab | 6.41M | 11.42M | 14.59M | 15.79M | 11.30M |
| Common stock | 0.01M | 0.00M | 0.01M | 0.05M | 0.05M |
| Capital stock | 0.01M | 0.00M | 0.01M | 58.05M | 58.02M |
| Retained earnings | -250.96M | -222.21M | -212.80M | -132.19M | -94.45M |
| Cash | 5.41M | 15.38M | 38.04M | 7.68M | 25.84M |
| Total current liabilities | 38.45M | 18.86M | 65.42M | 75.87M | 31.61M |
| Current deferred revenue | - | - | - | - | 0.20M |
| Net debt | 23.63M | 22.54M | 3.82M | 51.85M | 0.30M |
| Short term debt | 28.47M | 0.87M | 40.46M | 54.27M | 24.14M |
| Short long term debt | 28.07M | - | 38.64M | 53.36M | 24.14M |
| Short long term debt total | 29.04M | 37.92M | 41.86M | 59.53M | 26.14M |
| Other stockholder equity | 168.63M | 152.60M | 143.01M | 2.71M | 2.14M |
| Total current assets | 12.79M | 27.16M | 64.82M | 43.38M | 37.33M |
| Net receivables | 3.95M | 7.13M | 18.19M | 29.35M | 6.83M |
| Long term debt | - | 35.71M | - | 3.10M | 2.00M |
| Inventory | 2.67M | 3.40M | 6.17M | 3.87M | 2.71M |
| Accounts payable | 3.57M | 6.57M | 10.38M | 5.81M | 1.62M |
| Accumulated other comprehensive income | 5.14M | -8.37M | -0.70M | - | - |
| Non currrent assets other | 0.66M | 1.11M | 0.12M | 2.71M | 0.31M |
| Non current assets total | 2.98M | 5.66M | 6.90M | 7.99M | 2.02M |
| Capital lease obligations | 0.97M | 2.21M | 3.21M | 3.07M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.61M | -1.61M | -1.55M | -0.91M |
| Total cashflows from investing activities | - | -0.61M | - | - | - |
| Net borrowings | 0.00M | 0.07M | - | - | - |
| Total cash from financing activities | 18.97M | 20.21M | 95.99M | 30.54M | 28.95M |
| Net income | -28.75M | -26.15M | -80.61M | -37.74M | -12.39M |
| Change in cash | -9.98M | -22.70M | 30.40M | -17.99M | 13.70M |
| Begin period cash flow | 15.72M | 38.42M | 8.02M | 26.02M | 12.31M |
| End period cash flow | 5.74M | 15.72M | 38.42M | 8.02M | 26.02M |
| Total cash from operating activities | -28.95M | -42.30M | -63.98M | -46.98M | -14.33M |
| Issuance of capital stock | 18.97M | 21.26M | - | 0.00M | 9.87M |
| Depreciation | 0.98M | 1.00M | 0.75M | 2.00M | 0.71M |
| Dividends paid | - | - | - | 0.13M | - |
| Change to inventory | -0.49M | 0.54M | -3.71M | -1.15M | -1.28M |
| Change to account receivables | 0.84M | 8.98M | -1.32M | -22.82M | -0.71M |
| Sale purchase of stock | - | - | - | -776.54M | - |
| Other cashflows from financing activities | 18.97M | -1.33M | 95.92M | -0.55M | 9.87M |
| Capital expenditures | 0.00M | 0.61M | 1.61M | 1.55M | 0.91M |
| Change in working capital | -7.82M | 1.60M | 0.19M | -13.79M | -1.27M |
| Stock based compensation | 3.15M | 3.06M | 8.36M | 0.44M | 0.31M |
| Other non cash items | 3.50M | -21.80M | 7.33M | 0.84M | -2.35M |
| Free cash flow | -28.95M | -42.91M | -65.59M | -48.53M | -15.24M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALUR Allurion Technologies, Inc. |
- -% |
0.00 | - | 0.83 | 0.72 | - | 2.34 | -2.15 |
| ABT Abbott Laboratories |
1.27 1.18% |
108.52 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
1.87 1.85% |
102.86 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-2.75 0.88% |
309.64 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.27 0.55% |
48.51 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform offers the Allurion Program, a swallowable and procedure-less intragastric balloon for weight loss, as well as provides access to artificial intelligence-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company operates in Spain, France, Turkey, and internationally. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Shantanu K. Gaur M.D. | Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director | 1986 |
| Dr. Samuel G. Levy | Co-Founder | 1983 |
| Dr. Ram Chuttani M.D. | MD, Chief Medical Officer & Founding Partner | 1961 |
| Mr. Ojas A. Buch | Chief Operating Officer | 1973 |
| Mr. Brendan Michael Gibbons J.D. | Chief Legal Officer & Corporate Secretary | 1976 |
| Mr. Matt Wright | Vice President of People | NA |
| Ms. Joyce Johnson | Senior Vice President of Regulatory Affairs & Quality Assurance | NA |
| Dr. Shantanu K. Gaur M.D. | Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director | 1987 |
| Mr. Ojas A. Buch | Chief Operating Officer | 1974 |
| Mr. Brendan Michael Gibbons J.D. | Chief Legal & People Officer and Secretary | 1976 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.